STAAR Surgical Ownership
| STAA Stock | USD 29.10 0.92 3.26% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 50 M | Current Value 50 M | Avarage Shares Outstanding 41.9 M | Quarterly Volatility 5.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
STAAR |
STAAR Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of STAAR Surgical was at this time reported as 8.69. The company has Price/Earnings (P/E) ratio of 460.83. STAAR Surgical had not issued any dividends in recent years. The entity had 1:2 split on the 18th of May 1992. STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Staar Surgical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 692 people. To find out more about STAAR Surgical contact Thomas Frinzi at 626 303 7902 or learn more at https://www.staar.com.Besides selling stocks to institutional investors, STAAR Surgical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different STAAR Surgical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align STAAR Surgical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
STAAR Surgical Quarterly Liabilities And Stockholders Equity |
|
STAAR Surgical Insider Trades History
Less than 1% of STAAR Surgical are currently held by insiders. Unlike STAAR Surgical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against STAAR Surgical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of STAAR Surgical's insider trades
STAAR Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as STAAR Surgical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading STAAR Surgical backward and forwards among themselves. STAAR Surgical's institutional investor refers to the entity that pools money to purchase STAAR Surgical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Defender Capital, Llc. | 2024-09-30 | 677.6 K | Northern Trust Corp | 2024-09-30 | 627.8 K | Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 592.6 K | Ensign Peak Advisors Inc | 2024-09-30 | 529.2 K | Yunqi Capital Ltd | 2024-09-30 | 515.3 K | American Capital Management Inc | 2024-09-30 | 512.8 K | Armistice Capital, Llc | 2024-09-30 | 496.5 K | Royal Bank Of Canada | 2024-06-30 | 470.1 K | Bank Of America Corp | 2024-06-30 | 460.8 K | Broadwood Capital Inc | 2024-09-30 | 10.8 M | Blackrock Inc | 2024-06-30 | 7.5 M |
STAAR Surgical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific STAAR Surgical insiders, such as employees or executives, is commonly permitted as long as it does not rely on STAAR Surgical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases STAAR Surgical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
STAAR Surgical Outstanding Bonds
STAAR Surgical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. STAAR Surgical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most STAAR bonds can be classified according to their maturity, which is the date when STAAR Surgical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US85236FAA12 Corp BondUS85236FAA12 | View |
STAAR Surgical Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 31st of October 2024 An amendment to a previously filed Form 8-K | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether STAAR Surgical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STAAR Surgical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Staar Surgical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Staar Surgical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STAAR Surgical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STAAR Surgical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.018 | Earnings Share 0.44 | Revenue Per Share 6.962 | Quarterly Revenue Growth 0.103 | Return On Assets 0.0339 |
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STAAR Surgical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.